Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Sector news Specialty & Advanced Pharmaceuticals
04:22pKENNETH FRAZIER : Merck's Frazier to remain CEO beyond 2019
RE
03:11pDeal-making spree keeps investors upbeat about European M&A revival
RE
01:07pALEXION PHARMACEUTICALS : to Buy Syntimmune for Up to $1.2 Billion
DJ
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/25EUROPE : Oil boost and Italy budget hopes support European shares
RE
09/25ASTRAZENECA : Positive Data Bolsters Case For AstraZeneca's Imfinzi -- Update
DJ
09/25ASTRAZENECA : Data Show Cancer Drug Imfinzi Reduces Death Risk
DJ
09/25NOVARTIS : to Cut 2,000 Jobs Amid Revamp -- 2nd Update
DJ
09/25NOVARTIS : Cuts Over 2,000 Jobs in Switzerland as It Continues to Refocus -- Upd..
DJ
09/25NOVARTIS : Plans to Cut Over 2,000 Jobs in Switzerland
DJ
09/25NOVARTIS : Plans to Cut Over 2,000 Jobs in Switzerland
DJ
09/24ASTRAZENECA : EU Grants Marketing Authorization to AstraZeneca's Imfinzi
DJ
09/24ALEXION PHARMACEUTICALS : Soliris Meets Main Endpoint in Central Nervous System ..
DJ
09/24ASTRAZENECA : Mixed Results from Farxiga Trial
DJ
09/24SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/24As China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
09/21JOHNSON & JOHNSON : J&J Unit Agrees To Sell Sterilization Unit for $2.7 Billion
DJ
09/21EMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
09/21Triple Set of EMA Recommendations for Novartis Drugs
DJ
09/21GlaxoSmithKline, Innoviva Get Positive CHMP Opinion on Expanded COPD Indicati..
DJ
09/21ELI LILLY AND : Gets Positive CHMP Opinion for Migraine Drug Emgality
DJ
09/21AbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
09/21SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/20Animal health firm Elanco surges 41 percent on debut
RE
09/20WALL STREET STOCK EXCHANGE : Aurora Cannabis plans U.S. stock listing in October
RE
09/20ELI LILLY AND : Lilly Spinoff Elanco Animal Health Surges Early in Market Debut ..
DJ
09/20ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Navicixi..
DJ
09/20PFIZER : 20vPnC Vaccine Gets FDA Breakthrough-Therapy Designation
DJ
09/20Nestle aims to shed skin unit to focus on food, nutrition
RE
09/20Nestle aims to shed skin unit to focus on food, nutrition
RE
09/20EU approves fifth copy of AbbVie's $18 billion drug Humira
RE
09/20BAYER : Levels Sights On Weedkiller Verdict
DJ
09/20SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/19ELI LILLY AND : IPO of Lilly Unit Elanco Animal Health Prices Above Range at $24
DJ
09/19BAYER : Steps Up Fight Over Weed Killer Blamed for Cancer - Update
DJ
09/19COCA COLA : moving ahead with takeover of Nigeria's Chi juice
RE
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19German chemical industry warns against disruptive no-deal Brexit
RE
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/19SHIRE : Rule 2.9 Announcement
DJ
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/19BAYER : Steps Up Legal Fight Over Weed Killer Blamed for Cancer
DJ
09/18COCA COLA : buys Australia's kombucha maker Mojo
RE
09/18GLAXOSMITHKLINE : GSK grabs new drug development head from Boehringer
RE
09/18Aurora Cannabis Says No Current Deal on Partnership With Beverage Company
DJ
09/18COCA COLA : Aurora says no deal with beverage makers for weed-based drinks
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 32 862 M
EBIT 2018 14 513 M
Net income 2018 10 305 M
Debt 2018 29 518 M
Yield 2018 3,92%
P/E ratio 2018 14,09
P/E ratio 2019 12,11
EV / Sales 2018 5,22x
EV / Sales 2019 4,87x
Capitalization 142 B